Rezpegaldesleukin
23-358-05
Phase 2 small_molecule active
Quick answer
Rezpegaldesleukin for Moderate to Severe Atopic Dermatitis is a Phase 2 program (small_molecule) at Nektar Therapeutics UK Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Nektar Therapeutics UK Limited
- Indication
- Moderate to Severe Atopic Dermatitis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active